$65.44
-0.23-0.35%
Last update: Nov 6, 7:38 PM
PTC Therapeutics Inc
PTCTNASDAQ
PTC Therapeutics (PTCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
PTC Therapeutics (PTCT) last issued guidance on October 29, 2026 for fiscal year 2026. The company guided revenue in the range of $1.29B - $1.32B for the period.
Compared to prior guidance, PTC Therapeutics raised its revenue forecast from a prior range of $1.18B - $1.28B.
PTC Therapeutics has issued 23 guidance updates between January 9, 2023 and October 29, 2026. During this period, the company raised its outlook 8 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.27 | $0.31 | $-0.41 | $-0.33 |
| Actual | $0.94 | $0.92 | $-0.03 | $-1.67 |
| Surprise | +248.2% | +196.8% | +92.7% | -406.1% |
| Revenue | ||||
| Estimate | $306.2M | $292.7M | $227.5M | $295.4M |
| Actual | $357.8M | $360.5M | $272.6M | $164.7M |
| Surprise | +16.8% | +23.2% | +19.8% | -44.3% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.21 | $0.53 | $0.66 | $0.76 |
| Revenue | ||||
| Consensus | $330.2M | $317.1M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $0.94 | $0.27 | 248.2 % |
| Q2 | Jul 30, 2026 | $0.92 | $0.31 | 196.8 % |
| Q1 | May 7, 2026 | $-0.03 | $-0.41 | 92.7 % |
| Q4 | Feb 19, 2026 | $-1.67 | $-0.33 | -406.1 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $357.81M | $306.23M | 16.8 % |
| Q2 | Jul 30, 2026 | $360.52M | $292.70M | 23.2 % |
| Q1 | May 7, 2026 | $272.55M | $227.52M | 19.8 % |
| Q4 | Feb 19, 2026 | $164.68M | $295.44M | -44.3 % |
